SK702001A3 - Fkbp inhibitors - Google Patents

Fkbp inhibitors Download PDF

Info

Publication number
SK702001A3
SK702001A3 SK70-2001A SK702001A SK702001A3 SK 702001 A3 SK702001 A3 SK 702001A3 SK 702001 A SK702001 A SK 702001A SK 702001 A3 SK702001 A3 SK 702001A3
Authority
SK
Slovakia
Prior art keywords
compound
group
alkyl
optionally substituted
formula
Prior art date
Application number
SK70-2001A
Other languages
English (en)
Slovak (sk)
Inventor
Martin James Wythes
Michael John Palmer
Mark Ian Kemp
Malcolm Christian Mackenny
Robert John Maguire
James Francis Blake Jr
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of SK702001A3 publication Critical patent/SK702001A3/sk

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • A61K31/423Oxazoles condensed with carbocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/428Thiazoles condensed with carbocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Glass Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
SK70-2001A 1998-07-20 1999-07-01 Fkbp inhibitors SK702001A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9815696.1A GB9815696D0 (en) 1998-07-20 1998-07-20 Heterocyclics
PCT/IB1999/001227 WO2000005231A1 (en) 1998-07-20 1999-07-01 Fkbp inhibitors

Publications (1)

Publication Number Publication Date
SK702001A3 true SK702001A3 (en) 2001-12-03

Family

ID=10835773

Family Applications (1)

Application Number Title Priority Date Filing Date
SK70-2001A SK702001A3 (en) 1998-07-20 1999-07-01 Fkbp inhibitors

Country Status (45)

Country Link
US (2) US6166011A (es)
EP (1) EP1098894B1 (es)
JP (1) JP3545341B2 (es)
KR (1) KR20010083130A (es)
CN (1) CN1315951A (es)
AP (1) AP2001002045A0 (es)
AR (1) AR016501A1 (es)
AT (1) ATE225346T1 (es)
AU (1) AU756769B2 (es)
BG (1) BG105249A (es)
BR (1) BR9912307A (es)
CA (1) CA2338276C (es)
CO (1) CO5080761A1 (es)
CZ (1) CZ2001224A3 (es)
DE (1) DE69903319T2 (es)
DK (1) DK1098894T3 (es)
DZ (1) DZ2848A1 (es)
EA (1) EA200100051A1 (es)
EE (1) EE200100043A (es)
ES (1) ES2183567T3 (es)
GB (1) GB9815696D0 (es)
GT (1) GT199900113A (es)
HK (1) HK1040706A1 (es)
HN (1) HN1999000101A (es)
HR (1) HRP20010053A2 (es)
HU (1) HUP0103020A3 (es)
ID (1) ID27022A (es)
IL (1) IL140243A0 (es)
IS (1) IS5799A (es)
MA (1) MA26661A1 (es)
NO (1) NO20010299L (es)
NZ (1) NZ508839A (es)
OA (1) OA11586A (es)
PA (1) PA8477601A1 (es)
PE (1) PE20000867A1 (es)
PL (1) PL345705A1 (es)
PT (1) PT1098894E (es)
SI (1) SI1098894T1 (es)
SK (1) SK702001A3 (es)
TN (1) TNSN99146A1 (es)
TR (1) TR200100133T2 (es)
UA (1) UA60368C2 (es)
WO (1) WO2000005231A1 (es)
YU (1) YU83100A (es)
ZA (1) ZA200100229B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9815696D0 (en) * 1998-07-20 1998-09-16 Pfizer Ltd Heterocyclics
GB9815880D0 (en) * 1998-07-21 1998-09-16 Pfizer Ltd Heterocycles
GB0008939D0 (en) 2000-04-11 2000-05-31 Glaxo Group Ltd Process for preparing substituted benzimidazole compounds
JP2004526425A (ja) * 2000-11-28 2004-09-02 ワイス 前立腺癌の診断および治療に有用なfkbp核酸およびポリペプチドの発現分析
US7186518B2 (en) * 2003-11-21 2007-03-06 Dade Behring Inc. Method and composition useful for determining FK 506
WO2009154754A2 (en) * 2008-06-17 2009-12-23 Concert Pharmaceuticals, Inc. Synthesis of deuterated morpholine derivatives
DE102008060549A1 (de) 2008-12-04 2010-06-10 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Wirkstoff-Peptid-Konstrukt zur extrazellulären Anreicherung
TWI534142B (zh) 2011-03-15 2016-05-21 大正製藥股份有限公司 Azole derivatives
EP2705856A1 (en) 2012-09-07 2014-03-12 Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. Compounds for the treatment of neurodegenerative disorders
CN106138044B (zh) * 2016-07-15 2017-05-03 鲁俊东 一种治疗腰椎间盘突出症的药物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI91859C (fi) * 1987-06-17 1994-08-25 Eisai Co Ltd Analogiamenetelmä antiallergisena aineena aktiivisen bentsotiatsolijohdannaisen valmistamiseksi
FR2696176B1 (fr) * 1992-09-28 1994-11-10 Synthelabo Dérivés de pipéridine, leur préparation et leur application en thérapeutique.
CO4520280A1 (es) * 1993-10-26 1997-10-15 Boehringer Ingelheim Pharma Derivados de pirrolidina, inhibidores de la bioscientesis de leucotrienos
US5801187A (en) * 1996-09-25 1998-09-01 Gpi-Nil Holdings, Inc. Heterocyclic esters and amides
GB9700597D0 (en) * 1997-01-14 1997-03-05 Sandoz Pharma Uk Organic compounds
US5721256A (en) * 1997-02-12 1998-02-24 Gpi Nil Holdings, Inc. Method of using neurotrophic sulfonamide compounds
GB9815696D0 (en) * 1998-07-20 1998-09-16 Pfizer Ltd Heterocyclics
GB9815880D0 (en) * 1998-07-21 1998-09-16 Pfizer Ltd Heterocycles
US6495549B1 (en) * 1999-07-15 2002-12-17 Pfizer Inc FKBP inhibitors

Also Published As

Publication number Publication date
HN1999000101A (es) 2000-11-11
IL140243A0 (en) 2002-02-10
SI1098894T1 (en) 2002-12-31
DE69903319T2 (de) 2003-01-30
AU4385599A (en) 2000-02-14
ZA200100229B (en) 2002-04-09
EP1098894B1 (en) 2002-10-02
WO2000005231A1 (en) 2000-02-03
PA8477601A1 (es) 2000-09-29
HUP0103020A2 (hu) 2002-05-29
EE200100043A (et) 2002-06-17
AR016501A1 (es) 2001-07-04
EP1098894A1 (en) 2001-05-16
AU756769B2 (en) 2003-01-23
BR9912307A (pt) 2001-05-02
OA11586A (en) 2004-07-26
JP3545341B2 (ja) 2004-07-21
PT1098894E (pt) 2003-02-28
ID27022A (id) 2001-02-22
YU83100A (sh) 2003-04-30
DZ2848A1 (fr) 2003-12-01
PL345705A1 (en) 2002-01-02
DE69903319D1 (de) 2002-11-07
CO5080761A1 (es) 2001-09-25
UA60368C2 (uk) 2003-10-15
CN1315951A (zh) 2001-10-03
IS5799A (is) 2000-12-29
KR20010083130A (ko) 2001-08-31
GB9815696D0 (en) 1998-09-16
HUP0103020A3 (en) 2002-10-28
DK1098894T3 (da) 2002-10-28
PE20000867A1 (es) 2000-08-31
JP2002521381A (ja) 2002-07-16
GT199900113A (es) 2001-01-09
HK1040706A1 (zh) 2002-06-21
CZ2001224A3 (cs) 2001-08-15
AP2001002045A0 (en) 2001-03-31
NO20010299D0 (no) 2001-01-18
TNSN99146A1 (fr) 2005-11-10
US20040058905A1 (en) 2004-03-25
MA26661A1 (fr) 2004-12-20
CA2338276C (en) 2007-01-09
NO20010299L (no) 2001-03-15
ATE225346T1 (de) 2002-10-15
BG105249A (en) 2001-11-30
TR200100133T2 (tr) 2001-06-21
NZ508839A (en) 2003-01-31
US6166011A (en) 2000-12-26
EA200100051A1 (ru) 2001-08-27
ES2183567T3 (es) 2003-03-16
CA2338276A1 (en) 2000-02-03
HRP20010053A2 (en) 2001-12-31

Similar Documents

Publication Publication Date Title
CA2997382C (en) Substituted amino triazoles useful as human chitinase inhibitors
AU2003284984B2 (en) Gamma-aminoamide modulators of chemokine receptor activity
DE69910984T2 (de) Heterozyklische verbindungen als inhibitoren der rotamaseaktivität
WO2006102308A2 (en) Beta-lactamyl vasopressin v1b antagonists
HUT70613A (en) Compounds for inhibiting microsomal triglycerid transfer protein, their use for diminishing lipide level of sera and for treating atherosclerosis
SK772001A3 (en) Heterocyclic compounds as inhibitors of rotamase enzymes
AU2003284188A1 (en) Piperidinyl cyclopentyl aryl benzylamide modulators of chemokine receptor activity
AU2002342045C1 (en) Beta-lactamyl vasopressin Vla antagonists
JP2001513749A (ja) ブラジキニン作動薬としてのキノリンおよびベンズイミダゾール誘導体
SK702001A3 (en) Fkbp inhibitors
AU2002342045A1 (en) Beta-lactamyl vasopressin Vla antagonists
DE4429461A1 (de) Adhäsionsrezeptor-Antagonisten
US20090286797A1 (en) Novel Quinoxaline Derivatives and Their Medical Use
WO2007109098A2 (en) HYDROXY AND KETO-SUBSTITUTED β-LACTAMYL ALKANEDIOIC ACIDS
WO2005035492A1 (en) 3-SUBSTITUTED β-LACTAMYL VASOPRESSIN V1A ANTAGONISTS
US6495549B1 (en) FKBP inhibitors
WO2003014094A2 (de) Heterocyclylarylsulfonamide
MXPA00008623A (es) Compuestos heterociclicos como inhibidores de enzimas rotamasas